



RECEIVED  
MAY 07 2001  
TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Bernd RIEDL et al.

Serial No.: 09/772,920

Group Art Unit: 1626

Filed: February 7, 2001

Examiner: TO BE ASSIGNED

For: INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
NOV 01 2002  
TECH CENTER 1600/2900

SIR:


Pursuant to 37 CFR §1.97 and §1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is being submitted before the mailing of the first Office Action on the merits of the case; therefore, no fee is required herein.

Applicants respectfully request the Examiner to confirm review of such documents by initialing and returning the attached PTO-1449.

Respectfully submitted,

*Wrons Attorney*

  
Jennifer Branigan (Reg. No. 40,921)  
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd., Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 812-5305  
Internet Address: jbranigan@mwzb.com

Filed: 4 May 2001  
BAYER15P1-K:\Bayer\15P3\ids 2.wpd

RECEIVED  
MAY 10 2001  
TECHNOLOGY CENTER 2800

243-6333  
X310